Biocon Biologics is planning to raise $950 million through overseas bonds

September 14, 2024

Biocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its $1.2-billion debt from acquiring Viatris Inc.’s biosimilars business. The company has already prepaid $250 million and is exploring ways to reduce finance costs. The bond’s rating will determine its pricing.

More To Explore

UBS sells shares worth Rs 480 crore in Concord Biotech, IIFL Securities, 2 more stocks via block deals

UBS sold holdings in Concord Biotech, Five Star Business Finance, IIFL Securities, and Marksans Pharma through block deals, totaling Rs 480 crore. The largest sale

September 20, 2024

India’s Solar Energy Corporation mulls IPO, to invest $2.2 billion in renewables by 2030

State-owned Solar Energy Corporation of India (SECI) on Friday pledged to invest 180 billion rupees ($2.16 bln) in equity for renewable capacity expansion by 2030,

September 20, 2024

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information.

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003